A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

Recruiting

Phase 3

INCA033989 vs. Best Available TherapyA Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

Sponsor:

Incyte Corporation

Code:

NCT07623200

Conditions

Essential Thrombocythemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

INCA033989

Best Available Treatment

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-19. This information was provided to ClinicalTrials.gov by Incyte Corporation on 2026-08-06.